Stratrix
On the Record · Catalent

Catalent acquisitions, on the record

The businesses Catalent bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

BusinessDealWhenValue
Bettera Holdings, LLC ("Bettera Wellness")
Word for word“We acquired a leading position in consumer-preferred gummy and soft-chew formats for consumer health products with our acquisition of Bettera Holdings, LLC ( “Bettera Wellness” ) in fiscal 2022.” 10-K for 2022
acquisitionfiscal 2022—
facility in Anagni, Italy
Word for word“We expanded our capacity for oral and injectable products via our fiscal 2020 acquisition of a facility in Anagni, Italy, and our capacity for spray dried dispersion and dry powder inhaler manufacturing via our fiscal 2021 acquisition of a facility located near Boston, Massachusetts.” 10-K for 2022
acquisitionfiscal 2020—
Princeton, New Jersey cell therapy commercial-scale manufacturing facility
Word for word“Through continued inorganic investment in fiscal 2022, we acquired a fully operational, commercial-scale cell therapy campus in Princeton, New Jersey with 16 suites available for both autologous and allogeneic clinical and commercial manufacturing with potential further expansion.” 10-K for 2022
acquisitionfiscal 2022—
Oxford, U.K. manufacturing facility for biologic therapies and vaccines
Word for word“In fiscal 2022, we acquired each of Bettera Wellness, a manufacturer of a consumer-preferred gummy and other formats for consumer health products, a commercial-scale cell therapy manufacturing facility in Princeton, New Jersey, and a manufacturing facility for biologic therapies and vaccines near Oxford, U.K .” 10-K for 2022
acquisitionfiscal 2022—
Skeletal Cell Therapy Support SA ("Skeletal")
Word for word“Inorganic net revenue resulted from our acquisitions of Skeletal Cell Therapy Support SA (“Skeletal”), Delphi Genetics SA (“Delphi”) and the manufacturing and packaging assets of Acorda in fiscal 2021, as well as RheinCell Therapeutics GmbH (“RheinCell”), Bettera Wellness and a cell therapy commercial manufacturing facility and its operations in Princeton, New Jersey (“Princeton”) from Erytech Pharma S.A. (“Erytech”) in fiscal 2022.” 10-K for 2022
acquisitionfiscal 2021—
Delphi Genetics SA ("Delphi")
Word for word“Inorganic net revenue resulted from our acquisitions of Skeletal Cell Therapy Support SA (“Skeletal”), Delphi Genetics SA (“Delphi”) and the manufacturing and packaging assets of Acorda in fiscal 2021, as well as RheinCell Therapeutics GmbH (“RheinCell”), Bettera Wellness and a cell therapy commercial manufacturing facility and its operations in Princeton, New Jersey (“Princeton”) from Erytech Pharma S.A. (“Erytech”) in fiscal 2022.” 10-K for 2022
acquisitionfiscal 2021—
manufacturing and packaging assets of Acorda Therapeutics, Inc. (dry powder inhaler and spray dry manufacturing business)
Word for word“In fiscal 2021, we expanded our capacity and capabilities through five acquisitions for our Biologics segment and through the acquisition of a dry powder inhaler and spray dry manufacturing business from Acorda Therapeutics, Inc. (“Acorda”).” 10-K for 2022
acquisitionfiscal 2021—
RheinCell Therapeutics GmbH ("RheinCell")
Word for word“We completed the acquisition of RheinCell in August 2021.” 10-K for 2022
acquisitionWe completed the acquisition of RheinCell in August 2021.—
Princeton acquisition (cell therapy campus, Princeton, New Jersey)
Word for word“In April 2022, we completed the acquisition of Princeton.” 10-K for 2022
acquisitionIn April 2022, we completed the acquisition of Princeton.—
Metrics Contract Services (“Metrics”)
Word for word“In fiscal 2023, we acquired Metrics Contract Services (“Metrics”), an oral solids development and manufacturing business specializing in the manufacture of drugs containing highly potent active pharmaceutical ingredients.” 10-K for 2023
acquisitionfiscal 2023—
Princeton facility and operations (commercial-scale cell therapy manufacturing facility in Princeton, New Jersey)
Word for word“In fiscal 2022, we acquired a fully operational, commercial-scale cell therapy campus in Princeton with 16 suites available for both autologous and allogeneic clinical and commercial manufacturing.” 10-K for 2023
acquisition——
dry powder inhaler and spray dry manufacturing business from Acorda Therapeutics, Inc. (“Acorda”)
Word for word“In fiscal 2021, we expanded our capacity and capabilities through five acquisitions for our Biologics segment and through the acquisition of a dry powder inhaler and spray dry manufacturing business from Acorda Therapeutics, Inc. (“Acorda”).” 10-K for 2023
acquisitionfiscal 2021—
manufacturing facility for biologic therapies and vaccines near Oxford, U.K.
Word for word“In fiscal 2022, we acquired each of Bettera Wellness, a manufacturer of a consumer-preferred gummy and other formats for consumer health products, a commercial-scale cell therapy manufacturing facility in Princeton, and a manufacturing facility for biologic therapies and vaccines near Oxford, U.K.” 10-K for 2023
acquisitionfiscal 2022—
facility in Bolton, U.K.
Word for word“The year-over-year increase was primarily due to a $56 million increase in restructuring charges and a $71 million increase in fixed-asset impairment charges, partially offset by a $4 million gain from the sale of our facility in Bolton, U.K.” 10-K for 2023
divestiture——
commercial-scale cell therapy campus in Princeton
Word for word“In fiscal 2022, we acquired a fully operational, commercial-scale cell therapy campus in Princeton with 16 suites available for both autologous and allogeneic clinical and commercial manufacturing.” 10-K for 2024
acquisitionfiscal 2022—
As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year endedCash paid for acquisitions (net of cash acquired)Goodwill from acquisitions
2016-06-30$0—
2017-06-30$169.9 million$54.1 million
2018-06-30$748 million$342.3 million
2019-06-30$1.29 billion$840.6 million
2020-06-30$379 million$264 million
2021-06-30$147 million$56 million
2022-06-30$1.2 billion$572 million
2023-06-30$474 million$219 million
2024-06-30$0—

Deal filings since 2016

Read from Catalent’s annual reports (10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2024-09-06. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.